迪哲醫藥(688192.SH):董事長兼首席執行官張小林累計增持16.1萬股
格隆匯2月18日丨迪哲醫藥(688192.SH)公佈,截至2024年2月18日,公司董事長兼首席執行官張小林博士通過上海證券交易所繫統以集中競價方式累計增持公司股份16.0972萬股,佔公司總股本的0.0387%,增持金額508.0243萬元,已超過其本次增持計劃中擬增持股份金額區間下限。本次增持後,張小林博士直接持有公司731.0972萬股,佔公司總股本的1.7589%。
董事會祕書、首席財務官呂洪斌先生和副總經理、首席商務官吳清漪女士暫未進行本人增持計劃,呂洪斌先生和吳清漪女士基於對公司未來發展前景的信心以及對公司長期投資價值的認可,將按照相關增持計劃,在增持計劃實施時間內增持公司股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.